Artelo Biosciences Inc (ARTL)

Artelo Biosciences' stock price has declined approximately 90.26% over the past six months. Key events include public offerings in July and September 2025, positive interim Phase 2 results for ART27.13 in November 2025, and positive preclinical data for ART12.11 in July 2025. A peer-reviewed study on ART26.12 was published in December 2025. A peer-reviewed review on Fatty Acid Binding Protein 3 (FABP3) in November 2025 caused a 38.00% stock decline. A Presidential Executive Order expanding CBD research was commended by Artelo Biosciences in December 2025. The company's annual meeting of stockholders was adjourned on December 31, 2025, due to a lack of quorum.

As a clinical-stage biopharmaceutical company, Artelo Biosciences, Inc. is primarily focused on research and development rather than the commercial sale of products, so traditional demand seasonality is not directly applicable. The company's value and progress are driven by clinical trial outcomes, regulatory milestones, and potential partnerships, rather than seasonal fluctuations in product demand.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, to address unmet medical needs. Its product candidate pipeline includes ART27.13 for anorexia and weight loss associated with cancer, ART26.12 as a non-opioid analgesic, and ART12.11 for anxiety disorders, depression, PTSD, epilepsy, insomnia, pain, inflammation, and rare/orphan diseases.

Artelo Biosciences is headquartered in Solana Beach, California, United States, and maintains a European office in Dublin, Ireland.

Artelo Biosciences' brand reputation has been influenced by positive scientific advancements and corporate challenges. Positive developments include encouraging interim Phase 2 results for ART27.13 and positive preclinical data for ART12.11. The company's active participation in research, evidenced by the publication of peer-reviewed studies on ART26.12 and FABP3, also contributes to its reputation. However, the negative market reaction to the FABP3 review publication and the adjournment of the 2025 annual meeting due to a lack of quorum could have impacted investor confidence.

Institutional ownership of Artelo Biosciences, Inc. is between 1.64% and 2.43%, while individual insider ownership is approximately 0.47%. Major institutional shareholders include DRW Securities, LLC, Vanguard Group Inc, Morgan Stanley, Citigroup Inc, UBS Group AG, Fmr Llc, Bank Of America Corp /de/, Rothschild Investment Llc, and Royal Bank Of Canada.